X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

SMRT Sequencing for the HLA Complex: PacBio Goes to ASHI

Monday, October 20, 2014

This week marks the 40th annual meeting of the American Society for Histocompatibility and Immunogenetics, better known in the community as ASHI. The PacBio® team is looking forward to attending; after all, several organizations are now using Single Molecule, Real-Time (SMRT®) Sequencing specifically for resolving the incredibly complex genetic regions related to histocompatibility.

Earlier this year, we announced that two leading HLA typing institutions had adopted SMRT Sequencing to untangle this highly polymorphic set of genes: Anthony Nolan, a UK-based blood cancer charity that started the world’s first bone marrow registry, and HistoGenetics, a pioneer that has used sequence-based typing to characterize HLA regions in more than 14 million samples. We’re pleased to report that scientists from both organizations will be giving presentations at our ASHI workshop, Advances in Fully Phased HLA & KIR Typing Using SMRT® Sequencing.

The workshop will be held Wednesday, October 22, from noon to 2:00 p.m. Click here to register for the event or to request a recording if you won’t be at the Denver conference. Here are the speakers and topics:

The Challenge of HLA Diversity in 2014
Prof. Steve Marsh, Anthony Nolan Research Institute & University College London

Clinical HLA Typing on PacBio Platform
Nezih Cereb, M.D., President & CEO, Histogenetics

KIR Haplotypes: The Long and Short of It
Martin Maiers, Ph.D., Director, Bioinformatics Research, National Bone Marrow Donor Program

There are also a number of presentations and posters during the ASHI conference that will highlight the utility of SMRT Sequencing for characterizing the HLA complex, and we encourage attendees to stop by booth #307 to learn more.

Podium presentations:

Tuesday, October 21
Session: New & Improved NGS
2:00 p.m. – 3:30 p.m.
OR01: Automated Assembly of Complex Immunogenetic Haplotypes Using Long-Read, Single Molecule, Real-Time Sequencing of Fosmids
Richard J. Hall, Ph.D., Pacific Biosciences, Menlo Park, CA

OR05: Complete Resequencing of Extended Genomic Regions Using Fosmid Target Capture and Single Molecule Real-Time (SMRT®) Long Read Sequencing Technology
Daniel Geraghty, Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA

Thursday, October 23
Session: Scholar Awards
2:00 p.m. – 3:30 p.m.
OR59: Generation of 252 HLA Class I Genomic Sequences in a Single Sequencing Reaction Using DNA Barcodes and Single Molecule Real-Time (SMRT) DNA Sequencing Technology
Dr. Neema P. Mayor, Anthony Nolan, London, United Kingdom; UCL Cancer Institute, London, United Kingdom

Posters:

LBP04: Application of Single Molecule Real-Time (SMRT) Sequencing Technology for the Field 4 Level Genotyping of Classical HLA Loci

LBP07: Evaluation of Multiplexing Strategies for HLA Genotyping Using PacBio Sequencing Technologies

Please note: the PacBio RS II system is intended for Research Use Only and not for use in diagnostic procedures.

Subscribe for blog updates:

Archives